EUVIMEDEUVIMED entdecken
Open Access

Puberty induction in boys with congenital isolated hypogonadotropic hypogonadism

K D Kokoreva, I S Chugunov, M A Kareva, O B Bezlepkina

Problems of Endocrinology · 2023

DOI: 10.14341/probl13141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Problems of Endocrinology, 2023. Verfasst von K D Kokoreva und 3 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Research Centre. Hauptthemen laut MEDLINE: Hypogonadism. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND : Gonadotropin therapy in boys with congenital isolated hypogonadotropic hypogonadism helps to increase testes volume and induce spermatogenesis in comparison with testosterone therapy. However, difficulties with dose titration, partial therapy success, absence of generally accepted regimen protocols don’t allow to use this therapy in order to induce puberty in adolescents with Kallmann syndrome or normosmic hypogonadotropic hypogonadism. AIM : To assess the effectiveness of combination hormonal replacement therapy via human chorionic gonadotropin and recombinant follicle stimulation hormone in adolescents with congenital isolated normosmic hypogonadotropic hypogonadism and with Kallmann syndrome MATERIALS AND METHODS : This is an open single-center prospective non-controlled study. Boys with hypogonadotropic hypogonadism were receiving hormonal replacement therapy for 12 months. Initial dose of human chorionic gonadotropin was 500 IU per week. Initial dose of recombinant follicle stimulation hormone was 37.5 IU per week. Doses were doubled in 6 months. Antropometric data, Tanner stage, testes volumes, inhibin B and anti-Mullerian hormone (AMH) levels were evaluated in all the patients before the treatment, after 6 and 12 months of the therapy. RESULTS : 8 boys with hypogonadotropic hypogonadism were included into the study. Median age before therapy initiation was 15.7 years [15.33; 16.41]. In 12 months after the therapy initiation puberty development, testosterone increase from 0.44 [0.34;0.62] to 4.39 [0.88;10.51] nmol/l (p=0.012), AMH decrease from 35.70 [18.00;59.00] to 14.41 [11.60;16.65] ng/ml were noted in all the patients (p=0.017). Testes volumes increase and inhibin B level increase were not statistically significant. CONCLUSION : Gonadotropin therapy is effective in order to puberty initiation in adolescents with congenital hypogonadotropic hypogonadism. In helps to achieve not only androgenization, but also to Sertoli cells maturation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypogonadismMaleAdolescentHumansProspective StudiesTestosteroneChorionic GonadotropinAnti-Mullerian HormonePuberty

Substanzen

TestosteroneChorionic GonadotropinAnti-Mullerian Hormone

Autor:innen und Institutionen

  • Endocrinology Research Centre.

Zitieren

APA

Kokoreva, K. D., Chugunov, I. S., Kareva, M. A., & Bezlepkina, O. B. (2023). Puberty induction in boys with congenital isolated hypogonadotropic hypogonadism. Problems of Endocrinology. https://doi.org/10.14341/probl13141

Vancouver

Kokoreva KD, Chugunov IS, Kareva MA, Bezlepkina OB. Puberty induction in boys with congenital isolated hypogonadotropic hypogonadism. Problems of Endocrinology. 2023. doi:10.14341/probl13141

BibTeX
@article{Kokoreva2023,
  author = {Kokoreva, K D and Chugunov, I S and Kareva, M A and Bezlepkina, O B},
  title = {Puberty induction in boys with congenital isolated hypogonadotropic hypogonadism},
  journal = {Problems of Endocrinology},
  year = {2023},
  doi = {10.14341/probl13141}
}
Kostenlos starten →